Abstract
Apixaban, a Factor Xa inhibitor, has been shown to confer superior net clinical benefit compared to warfarin in the management of patients with non-valvular atrial fibrillation (NVAF). While warfarin effect can be easily monitored using INR measurements, assessment of anti-Factor Xa activity level is currently not readily available. Effects of direct oral anticoagulants have been shown to be related to their plasma levels.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
